INFLUENCE OF SEX ON PLATELET RESPONSE TO ASPIRIN AND TICAGRELOR
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(17)33412-5
Abstract: Background: Aspirin's benefits for prevention of coronary artery disease differs by sex. While aspirin equally suppresses its target COX-1 in both sexes, platelets in women treated with aspirin retain greater platelet reactivity to COX-1-independent agonists… read more here.
Keywords: influence sex; sex platelet; platelet response; platelet ... See more keywords
NOVEL METHOD FOR ASSESSING PLATELET RESPONSE TO ADP: TECHNICAL VALIDATION STUDY OF THE AGGREGUIDE A-100 ADP ASSAY
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)30785-3
Abstract: The recently FDA approved AggreGuide A-100 ADP (A100ADP) assay includes appropriate fluid dynamic characteristics in a microfluidic reaction chamber with whole blood in motion to measure P2Y12 inhibitor effects. The ability of the A-100ADP assay… read more here.
Keywords: 100 adp; novel method; method assessing; aggreguide 100 ... See more keywords
Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study.
Sign Up to like & getrecommendations! Published in 2023 at "Platelets"
DOI: 10.1080/09537104.2022.2159019
Abstract: Increased platelet destruction is central in the pathogenesis of immune thrombocytopenia. However, impaired platelet production is also relevant and its significance underlies the rationale for treatment with thrombopoietin receptor agonists (TPO-RAs). Previous studies have associated… read more here.
Keywords: platelet; immune thrombocytopenia; complement activation; platelet response ... See more keywords
Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Haematology"
DOI: 10.1111/bjh.15573
Abstract: Avatrombopag, an oral thrombopoietin receptor agonist, was compared with placebo in a 6‐month, multicentre, randomised, double‐blind, parallel‐group Phase 3 study, with an open‐label extension phase, to assess the efficacy and safety of avatrombopag (20 mg/day)… read more here.
Keywords: phase; chronic immune; receptor agonist; immune thrombocytopenia ... See more keywords